Prothena/$PRTA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Prothena

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Ticker

$PRTA
Primary listing

Industry

Biotechnology

Headquarters

Dublin, Ireland

Employees

163

Prothena Metrics

BasicAdvanced
$360M
-
-$2.05
-0.08
-

What the Analysts think about Prothena

Analyst ratings (Buy, Hold, Sell) for Prothena stock.

Bulls say / Bears say

Prothena expects initial Phase 1 ASCENT data for its wholly-owned PRX012 Alzheimer’s program in August 2025, which if positive could materially de-risk one of its leading pipeline assets and drive significant valuation upside.
Partner Roche has advanced prasinezumab into Phase 3 development for early-stage Parkinson’s disease, positioning Prothena to benefit from potential milestone payments and royalties pending successful trial outcomes.
Prothena’s partnerships carry up to $105 million in contingent milestone payments expected by 2026, providing non-dilutive financing catalysts as clinical programs progress and supporting the company’s cash runway.
The Phase 3 AFFIRM-AL trial for birtamimab failed to meet both its primary endpoint of time to all-cause mortality and its secondary endpoints, leading Prothena to discontinue its development and creating a significant void in its rare amyloid franchise.
The announcement of an approximate 63% workforce reduction as part of a corporate restructuring may delay development timelines across Prothena’s wholly-owned and partnered programs, potentially undermining program execution and increasing execution risk.
PRTA shares have declined over 53% year-to-date, reflecting waning investor confidence and heightening the risk of further downside absent compelling positive clinical or financial catalysts.
Data summarised monthly by Lightyear AI. Last updated on 20 Jul 2025.

Prothena Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Prothena Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRTA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs